Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

Vecchio, Sharon J. Del; Ellis, Robert J.

doi:10.15586/jkcvhl.2018.109

Cited by 25 publications

(26 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ccRCC is one of the most common kidney malignancy [29] and accounts for ~3% of adult cancer [30]. Five-year survival of ccRCC patients with metastasis is only 12% and almost 20-40% patients would experience distant metastasis [5, 6].…”

Section: Discussionmentioning

confidence: 99%

Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis

Wang

Chai

2019

BioMed Research International

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) was the most aggressive histological type of renal cell carcinoma (RCC) and accounted for 70–80% of cases of all RCC. The aim of this study was to identify the potential biomarker in ccRCC and explore their underlying mechanisms. Four profile datasets were downloaded from the GEO database to identify DEGs. GO and KEGG analysis of DEGs were performed by DAVID. A protein–protein interaction (PPI) network was constructed to predict hub genes. The hub gene expression within ccRCC across multiple datasets and the overall survival analysis were investigated utilizing the Oncomine Platform and UALCAN dataset, separately. A meta-analysis was performed to explore the relationship between the hub genes: EGFR and ccRCC. 127 DEGs (55 upregulated genes and 72 downregulated genes) were identified from four profile datasets. Integrating the result from PPI network, Oncomine Platform, and survival analysis, EGFR, FLT1, and EDN1 were screened as key factors in the prognosis of ccRCC. GO and KEGG analysis revealed that 127 DEGs were mainly enriched in 21 terms and 4 pathways. The meta-analysis showed that there was a significant difference of EGFR expression between ccRCC tissues and normal tissues, and the expression of EGFR in patients with metastasis was higher. This study identified 3 importance genes (EGFR, FLT1, and EDN1) in ccRCC, and EGFR may be a potential prognostic biomarker and novel therapeutic target for ccRCC, especially patients with metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis

Wang

Chai

2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Cabozantinib has therapeutic effects on metastatic castration-resistant prostate cancer (mCRPC) by eliminating the bone metastasis of mCRPC with pain relief [74,75]. Cabozantinib was approved as a first and second-line treatment for advanced/metastatic renal cell carcinoma based on two clinical trials [76].…”

Section: Tyrosine Kinase Inhibitor Therapymentioning

confidence: 99%

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

Yong

et al. 2019

Cells

View full text Add to dashboard Cite

Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.

show abstract

“…ccRCC ranks first in incidence amongst all histological types of kidney malignancies (19), and accounts for nearly 3% of all types of adult malignancies (20). Although the 5-year survival rate of patients with ccRCC at the early stage is >90%, it decreases to 10% in patients with advanced ccRCC (5), and >100,000 patients succumb to ccRCC per year worldwide (21).…”

Section: Discussionmentioning

confidence: 99%

A novel prognostic nomogram based on 5 long non‑coding RNAs in clear cell renal cell carcinoma

2019

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is the most common and invasive histological subtype of all kidney malignancies, with high levels of incidence and mortality. In the present study, long non-coding (lnc)RNA expression profiles of patients with ccRCC from The Cancer Genome Atlas database were comprehensively analyzed to identify differentially expressed lncRNAs (DElncRNAs). The patients with ccRCC were then divided into training and validation cohorts. Univariate and LASSO regression analyses were performed to select the most significant survival-associated candidate DElncRNAs in the training cohort. Multivariate Cox regression analysis was then performed to develop a risk score formula and a prognostic nomogram for predicting 3-and 5-year overall survival (OS). The accuracies of the nomogram predictions were evaluated by determining the area under the receiver operating characteristic curve (AUC) and a calibration plot. Finally, functional enrichment analysis and protein-protein interaction network prediction were implemented to predict the functions and molecular mechanisms of the candidate DElncRNAs in ccRCC. A total of 1,553 DElncRNAs were identified, and 5 candidate DElncRNAs (AC026992.2, AC245041.2, LINC00524, LINC01956 and LINC02080) were included in the nomogram. The AUC values for 3-and 5-year overall survival in the training cohort were 0.768 and 0.814, respectively, which were increased compared with that based on the clinical index (0.760 and 0.694, respectively). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed that the 521 mRNAs highly associated with 5 DElncRNAs were primarily involved in 17 terms and 25 pathways, respectively. Based on the 5 DElncRNAs, a novel and convenient prognostic nomogram for predicting 3-and 5-year OS for patients with ccRCC was developed. The results of the present study may be conducive to the development of a precise predictive tool for the prognosis of ccRCC and may provide information regarding the molecular mechanisms of ccRCC. However, additional experimental in vitro and in vivo studies investigating lncRNAs may be required.

show abstract

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

Cited by 25 publications

References 33 publications

Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis

Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis

The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

A novel prognostic nomogram based on 5 long non‑coding RNAs in clear cell renal cell carcinoma

Contact Info

Product

Resources

About